Sugi Predict

Sugi Predict / Targets / CD79B

CD79B

B-cell antigen receptor complex-associated protein beta chain · P40259 · CD79B on Sugi Atlas →

73 patent compounds predicted against CD79B, 54 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12732611 SCHEMBL12732611 0.64 1/20
SCHEMBL13096782 SCHEMBL13096782 0.64 1/20
SCHEMBL13105971 SCHEMBL13105971 0.64 1/20
SCHEMBL21122194 SCHEMBL21122194 0.64 1/20
SCHEMBL26219659 SCHEMBL26219659 0.64 1/20
SCHEMBL31309982 SCHEMBL31309982 0.64 1/20
SCHEMBL21839508 SCHEMBL21839508 0.60 1/20
SCHEMBL21882835 SCHEMBL21882835 0.60 1/20
SCHEMBL22215049 SCHEMBL22215049 0.60 1/20
SCHEMBL21882821 SCHEMBL21882821 0.58 1/20
SCHEMBL22856799 SCHEMBL22856799 0.58 1/20
SCHEMBL22856800 SCHEMBL22856800 0.58 1/20
SCHEMBL22856823 SCHEMBL22856823 0.58 1/20
SCHEMBL26281966 SCHEMBL26281966 0.58 1/20
SCHEMBL21839580 SCHEMBL21839580 0.57 1/20
SCHEMBL21839581 SCHEMBL21839581 0.57 1/20
SCHEMBL22206496 SCHEMBL22206496 0.57 1/20
SCHEMBL23633905 SCHEMBL23633905 0.57 1/20
SCHEMBL23914866 SCHEMBL23914866 0.57 1/20
SCHEMBL23633859 SCHEMBL23633859 0.57 1/20

Clinical trials — most relevant to CD79B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases PHASE4COMPLETED
Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis PHASE3UNKNOWN
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency PHASE3RECRUITING
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib PHASE3COMPLETED
CD19/79b Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma PHASE1/PHASE2WITHDRAWN
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies PHASE2UNKNOWN
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma PHASE1/PHASE2RECRUITING
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib PHASE2COMPLETED
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia PHASE2RECRUITING
CD19/70 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1/PHASE2UNKNOWN
Quantitating the Impact of Plerixafor PHASE1/PHASE2UNKNOWN
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma PHASE1RECRUITING
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE PHASE1RECRUITING
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma PHASE1RECRUITING
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma PHASE1ACTIVE_NOT_RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN nanUNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL nanUNKNOWN
Molecular and Cellular Characterization of MALT Lymphoma nanNOT_YET_RECRUITING
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL) nanUNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma nanNOT_YET_RECRUITING
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry nanUNKNOWN
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CD79B binder may also engage these)

ProteinNameSimilarity
P15530 — 0.993 P15530 →
P0CAN6 — 0.991 P0CAN6 →
P40293 — 0.989 P40293 →
P11911 — 0.986 P11911 →
P11912 — 0.984 P11912 →
P97710 — 0.981 P97710 →
Q7Z6M3 — 0.981 Q7Z6M3 →
Q9ET39 — 0.981 Q9ET39 →
Q7TSA3 — 0.980 Q7TSA3 →
O95727 — 0.980 O95727 →
P50283 — 0.980 P50283 →
Q8BG84 — 0.979 Q8BG84 →
Q13291 — 0.978 Q13291 →
Q2YFS1 — 0.978 Q2YFS1 →
P10747 — 0.978 P10747 →
Q8K4F0 — 0.978 Q8K4F0 →
P97797 — 0.978 P97797 →
Q9BZW8 — 0.977 Q9BZW8 →
Q9QUM4 — 0.977 Q9QUM4 →
Q2YFS2 — 0.977 Q2YFS2 →
Q7Z6A9 — 0.977 Q7Z6A9 →
Q2YFS3 — 0.977 Q2YFS3 →
Q15762 — 0.977 Q15762 →
Q07763 — 0.977 Q07763 →
Q495A1 — 0.977 Q495A1 →
Q02242 — 0.976 Q02242 →
P42069 — 0.976 P42069 →
P43303 — 0.976 P43303 →
Q149L7 — 0.976 Q149L7 →
Q62875 — 0.975 Q62875 →